Wen-zhao F. Zhong
Expertise in
7
conditions

Wen-zhao F. Zhong

106 Zhongshan 2nd Rd, 
Guangzhou, CN 
Expertise in
7
conditions
106 Zhongshan 2nd Rd, 
Guangzhou, CN 

Overview

Wen-zhao Zhong practices practicing medicine in Guangzhou, China.

Zhong is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Endoscopy.

They are actively involved in clinical research, co-authoring 240 peer reviewed articles and participating in 2 clinical trials.

Locations

106 Zhongshan 2nd Rd, Guangzhou, 510080, China
Other Locations
China P.R, Beijing, 100191, China
106 Zhongshan 2nd Road, Guangzhou, 510080, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Nivolumab, Carboplatin, Nab-Paclitaxel
Study Phase: Phase 2
Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-mutant Stage II-IIIB NSCLC: A Single-arm, Open-label Prospective Study
Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-mutant Stage II-IIIB NSCLC: A Single-arm, Open-label Prospective Study
Enrollment Status: Unknown
Publish Date: July 08, 2024
Intervention Type: Biological, Drug
Study Drugs: Sintilimab, Carboplatin, Nab Paclitaxel
Study Phase: Phase 2
View 1 Less Clinical Trial

240 Total Publications

FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36.
FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36.
Journal: Science translational medicine
Published: August 26, 2026

Frequently Asked Questions about Wen-zhao F. Zhong

Is Wen-zhao F. Zhong a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Wen-zhao F. Zhong is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Wen-zhao F. Zhong participate in research or clinical trials?

Yes. Wen-zhao F. Zhong has published 240 articles and abstracts on conditions like Lung Cancer. You can view a list of Wen-zhao F. Zhong's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhong's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile